Nathalie Cools
Universiteit Antwerpen
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nathalie Cools as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06715605 · A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MSUniversity Hospital, Antwerp · withdrawn · Multiple Sclerosis · principal investigator
- Ph1NCT02618902 · A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical TrialUniversity Hospital, Antwerp · completed · Multiple Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.Proc Natl Acad Sci U S A · 2010304 citationsRCR 6.4
- Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.Blood · 2017200 citationsRCR 5.8
- 100 citationsRCR 3.0
- 88 citationsRCR 2.1
- Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training.Eur J Neurol · 201669 citationsRCR 3.3
- 12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis.Mediators Inflamm · 201647 citationsRCR 2.0
- Human tears reveal insights into corneal neovascularization.PLoS One · 201236 citationsRCR 1.5
- GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.Clin Cancer Res · 201635 citationsRCR 1.2
- High Intensity Aerobic and Resistance Exercise Can Improve Glucose Tolerance in Persons With Multiple Sclerosis: A Randomized Controlled Trial.Am J Phys Med Rehabil · 201730 citationsRCR 1.6
- 30 citationsRCR 6.8